ÂÜÀòÂÒÂ×

Kathleen Weber was named Executive Vice President, Business Unit Leader for Molecular Solutions in January 2019 and promoted to President in January 2022. In this role, she has oversight for the commercial, operational and financial performance of the business unit, which is also known as DNA Genotek and includes the Novosanis and Diversigen wholly owned subsidiaries. Kathy joined OraSure in 2012 as the Senior Vice President and General Manager, Consumer Products. Her role evolved from 2012 to 2018 to also include at various points in time managing the Emerging Disease Portfolio and leading the development of OraSure’s corporate strategy. Prior to joining OraSure, Ms. Weber held several senior commercial leadership positions at Pfizer, Johnson and Johnson and Schering–Plough. Ms. Weber began her career in the financial services industry and held various positions in U.S. and global marketing and operations at Chase Manhattan Bank, now part of JP Morgan Chase. Ms. Weber received a B.S. degree in business administration from Georgetown University and earned an M.B.A. from New York University’s Stern School of Business.